Jeffrey M. Zirger,

Lead, Information Collection Review Office, Office of Public Health Ethics and Regulations, Office of Science, Centers for Disease Control and Prevention.

[FR Doc. 2024–30480 Filed 12–19–24; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Safety and Occupational Health Study Section; Notice of Solicitation of Nominations for Appointment; Correction

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice; correction.

SUMMARY: In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC), within the Department of Health and Human Services (HHS), is seeking nominations for membership on the Safety and Occupational Health Study Section (SOHSS). SOHSS consists of 20 experts in fields associated with occupational medicine and nursing, industrial hygiene, occupational safety and engineering, toxicology, chemistry, safety and health education, ergonomics, epidemiology, economic science, psychology, pulmonary pathology/physiology, and social science.

DATES: Nominations for membership on SOHSS must be received no later than January 31, 2025. Packages received after this time will not be considered for the current membership cycle.

ADDRESSES: All nominations should be mailed to Dr. Michael Goldcamp, 1095 Willowdale Road, Morgantown, West Virginia 26505 or emailed to *MGoldcamp@cdc.gov.*

FOR FURTHER INFORMATION CONTACT: Michael Goldcamp, Ph.D., Scientific Review Officer, Office of Extramural Programs, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, 1095 Willowdale Road, Morgantown, West Virginia 26505. Telephone: (304) 285–5951; email: *MGoldcamp@cdc.gov.*

SUPPLEMENTARY INFORMATION:

Correction

Notice is hereby given of a correction in the **SUPPLEMENTARY INFORMATION** section of the original solicitation of nominations notice, which was published in the **Federal Register** on December 2, 2024, 89 FR 95214.

The notice is being amended to remove the sentence concerning Special Government Employees, since members of the Safety and Occupational Health Study Section serve as Peer Review Consultants. The **SUPPLEMENTARY INFORMATION** section should read as follows:

SUPPLEMENTARY INFORMATION: Nominations are sought for individuals who have the expertise and qualifications necessary to contribute to the accomplishment of the objectives of the Safety and Occupational Health Study Section (SOHSS). Nominees will be selected based on expertise in the fields of occupational medicine and nursing, industrial hygiene, occupational safety and engineering, toxicology, chemistry, safety and health education, ergonomics, epidemiology, economic science, psychology, pulmonary pathology/physiology, and social science. Members may be invited to serve up to four-year terms. Selection of members is based on candidates' qualifications to contribute to the accomplishment of SOHSS objectives (*https://www.cdc.gov/faca/committees/sohss.html*).

Department of Health and Human Services (HHS) policy stipulates that committee membership be balanced in terms of points of view represented and the committee's function. Appointments shall be made without discrimination on the basis of age, race, ethnicity, gender, sexual orientation, gender identity, HIV status, disability, and cultural, religious, or socioeconomic status. Nominees must be U.S. citizens and cannot be full-time employees of the U.S. Government. Current participation on Federal workgroups or prior experience serving on a Federal advisory committee does not disqualify a candidate; however, HHS policy is to avoid excessive individual service on advisory committees and multiple committee memberships. The Centers for Disease Control and Prevention (CDC) reviews potential candidates for SOHSS membership each year and provides a slate of nominees for consideration to the Secretary of HHS for final selection. HHS notifies selected candidates of their appointment near the start of the term in October 2025, or as soon as the HHS selection process is completed. Note that the need for different expertise varies from year to year and a candidate who is not selected in one year may be reconsidered in a subsequent year.

Candidates should submit the following items:

- Current curriculum vitae, including complete contact information (telephone numbers, mailing address, email address).
- At least one letter of recommendation from person(s) not employed by HHS. Candidates may submit letter(s) from current HHS employees if they wish, but at least one letter must be submitted by a person not employed by an HHS agency (*e.g.,* CDC, National Institutes of Health, Food and Drug Administration).

Nominations may be submitted by the candidate or by the person/organization recommending the candidate.

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2024–30410 Filed 12–19–24; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award of a Sole Source Cooperative Agreement to Fund Secretaria Ejecutiva del Consejo de Ministros de Salud de Centroamerica y Republica Dominicana (SE–COMISCA)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award of approximately $5,000,000, with an expected total funding of approximately $25,000,000 over a 5-year period, to SE–COMISCA. The award will build upon previous efforts by the CDC in collaboration with Ministries of Health of Central America and the Dominican Republic (SE–COMISCA).

DATES: The period for this award will be September 30, 2025 through September 29, 2030.

FOR FURTHER INFORMATION CONTACT: Broderick Yoerg, Division of Global Health Protection, Global Health Center, Centers for Disease Control and Prevention, 1600 Clifton Rd., Atlanta, GA 30329, email: *DGHPNOFOs@cdc.gov,* telephone: 404–234–0666.

SUPPLEMENTARY INFORMATION: The sole source award will target increased capacity at the national and subnational level to implement and achieve outbreak/epidemic/pandemic control in line with US Government (USG) and CDC strategy. This collaborative effort has led to significant progress in various areas under the Global Health Strategic Framework, including One Health workshops in multiple countries to prioritize zoonotic diseases and the development of a joint action plan for Central America.

SE–COMISCA is the only entity that can carry out this work, as it will improve outbreak control capacity, better integration between health systems, and increased equity in healthcare access for all populations, especially those historically marginalized.

Summary of the Award

Recipient: SE–COMISCA

Purpose of the Award: The purpose of this award is to support Global Health Security goals in Central America and the Dominican Republic by collaborating with MOH and other partners. Efforts will focus on reaching underserved populations, prioritizing equity to build resilient health systems that protect vulnerable groups.

Amount of Award: $5,000,000 in Federal Fiscal Year (FFY) 2025 funds, with a total estimated $25,000,000 for the 5-year period of performance, subject to availability of funds.

Authority: This program is authorized under section 307 of the Public Health Service Act [42 U.S.C. 24*l*) and Section 301(a)[42 U.S.C. 24*l*(a) of the Public Health Service Act.

Period of Performance: September 30, 2025 through September 29, 2030.

Dated: December 10, 2024.

Terrance Perry,

Acting Director, Office of Grants Services, Centers for Disease Control and Prevention.

[FR Doc. 2024–30223 Filed 12–19–24; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket No. CDC–2020–0046; NIOSH–233–C]

Hazardous Drugs: NIOSH List of Hazardous Drugs in Healthcare Settings, 2024 and Final Reevaluation Determinations for Liraglutide and Pertuzumab

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: General notice.

SUMMARY: The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), in the Department of Health and Human Services (HHS), announces the publication of the *NIOSH List of Hazardous Drugs in Healthcare Settings, 2024,* as well as final reevaluation determinations removing the drugs liraglutide and pertuzumab from the *NIOSH List of Hazardous Drugs in Healthcare Settings*.

DATES: The documents announced in this notice are available on December 20, 2024.

ADDRESSES: The documents announced in this notice are available in the docket at *www.regulations.gov* and through the NIOSH Hazardous Drug Exposures in Healthcare website at *https://www.cdc.gov/niosh/healthcare/hazardous-drugs/index.html*.

FOR FURTHER INFORMATION CONTACT: Jerald Ovesen, NIOSH, Robert A. Taft Laboratories, 1090 Tusculum Avenue, MS–C15, Cincinnati, OH 45226, telephone: (513)533–8472 (not a toll-free number), email: *jovesen@cdc.gov*.

SUPPLEMENTARY INFORMATION: This notice is organized as follows: